30 results match your criteria: "McMaster University and Juravinski Cancer Centre[Affiliation]"
Clin Oncol (R Coll Radiol)
February 2010
Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada.
After orchidectomy and staging, patients with clinical stage I (CS I) non-seminomatous testicular cancer (NSTC) may be offered chemotherapy, surgery or active surveillance. The optimal postoperative approach is undefined. Therefore, a systematic review was carried out to assess these management approaches.
View Article and Find Full Text PDFJ Clin Oncol
October 2009
Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada.
Cancer patients with solid tumors or hematologic malignancies receive most of their cancer treatment as outpatients. Thromboembolism, when it occurs, complicates the clinical care of these patients because of the associated morbidity and the need for anticoagulant treatment. It would seem that prevention of venous thromboembolism in these patients would be worthwhile.
View Article and Find Full Text PDFJ Clin Oncol
October 2009
Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario.
For more than 50 years, heparin and vitamin K antagonists (VKAs) have been the anticoagulant drugs used to prevent and treat thrombosis. Low molecular weight heparins (LMWHs) are more recent and have been available for approximately 20 years. Patients with cancer are members of a unique patient population because of their high risk for thrombosis and the risk of anticoagulant-related bleeding.
View Article and Find Full Text PDFIntegr Cancer Ther
June 2007
McMaster University and Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada.
Silymarin (Silybum marianum [L.] Gaertn. [Asteraceae]) is a promising agent for cancer prevention, adjuvant cancer treatment, and reduction of iatrogenic toxicity.
View Article and Find Full Text PDFAnn Intern Med
January 2007
McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada.
Background: Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat idiopathic thrombocytopenic purpura (ITP).
Purpose: To systematically review the literature on the efficacy and safety of rituximab for the treatment of adults with ITP.
Data Sources: MEDLINE, EMBASE, the Cochrane Library, abstracts from the American Societies of Hematology and Clinical Oncology annual meetings, and bibliographies of relevant articles and reviews were searched in duplicate until April 2006.